Navigation Links
PRA Executive to Present at Outsourcing Conference
Date:7/20/2011

RALEIGH, N.C., July 20, 2011 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that the head of our Scientific and Medical Affairs group, Kent Thoelke, will discuss critical issues in medical informatics and feasibility at the 3rd Annual Effective Business Development Outsourcing Relationships Conference being held 19-21 July 2011 in Philadelphia.

On Thursday, 21 July, Mr. Thoelke will co-host the session, "Rising to the Challenge of Global Feasibility through Medical Informatics." The presentation's highlights include using medical informatics as a data-driven approach to plan clinical trials, practical considerations for particular patient populations, and how to develop multi-country scenarios to meet enrollment milestones.

In his role as Senior Vice President at PRA, Mr. Thoelke directs our medical informatics and therapeutic expertise programs, providing scientific and strategic oversight of product development to empower project teams as they execute clinical trials on behalf of our clients. He has over 19 years of wide-ranging experience in global drug development and device industry. Having visited over 40 countries, he is familiar with the global drug development environment, and has established relationships with therapeutic experts in numerous indications around the world.

PRA's Medical Informatics group, which serves as a key component of our Scientific and Medical Affairs division, leads the industry in advancing evidence-based approaches for protocol validation, study feasibility and patient access.  To enhance global accrual rates for clinical trials, PRA has focused on mining public and private databases to create a proprietary methodology for patient and site access.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency.  PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge.  Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs.  But at PRA, we are looking to the future, not the past.  Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.


'/>"/>
SOURCE PRA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
2. AquaStar Holdings, Inc. Subsidiary Appoints Former Beckman Coulter Executive as Vice President of Operations
3. Dr. David Heimbrook Appointed Chief Executive Officer of SAIC-Frederick, Inc.
4. Netsmart Technologies Names Michael Valentine as Chief Executive Officer
5. Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director
6. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
7. Ed Weimer Joins Delta Point, Inc. as Executive Account Director
8. Pearl Therapeutics Appoints Charles (Chuck) Bramlage President and Chief Executive Officer
9. The Clearity Foundation Hires Hillary Theakston as Executive Director
10. Savient Pharmaceuticals Announces Executive Appointments
11. IDRI Announces Appointment of H. Stewart Parker as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):